Evelo Biosciences, Inc.
EVLO · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $78,554 | $83,643 | $69,616 | $63,128 |
| G&A Expenses | $29,912 | $31,753 | $22,270 | $23,229 |
| SG&A Expenses | $29,912 | $31,753 | $22,270 | $23,229 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $108,466 | $115,396 | $91,886 | $86,357 |
| Operating Income | -$108,466 | -$115,396 | -$91,886 | -$86,357 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$5,131 | -$6,352 | -$1,371 | $885 |
| Pre-Tax Income | -$113,597 | -$121,748 | -$93,257 | -$85,472 |
| Tax Expense | $930 | $428 | $409 | $190 |
| Net Income | -$114,527 | -$122,176 | -$93,666 | -$85,662 |
| % Margin | – | – | – | – |
| EPS | -26.28 | -46.18 | -47.45 | -53.49 |
| % Growth | 43.1% | 2.7% | 11.3% | – |
| EPS Diluted | -26.28 | -46.18 | -47.45 | -53.49 |
| Weighted Avg Shares Out | 4,358 | 2,646 | 1,974 | 1,602 |
| Weighted Avg Shares Out Dil | 4,358 | 2,646 | 1,974 | 1,602 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $4 | $0 | $1 |
| Interest Expense | $4,672 | $3,612 | $2,109 | $1,049 |
| Depreciation & Amortization | $2,060 | $2,216 | $2,026 | $2 |
| EBITDA | -$106,345 | -$115,396 | -$89,860 | -$84,421 |
| % Margin | – | – | – | – |